Skip to main content
Erschienen in: Advances in Therapy 10/2020

28.08.2020 | Original Research

An Analysis of Medication Prescriptions for Hypertension in Urban and Rural Residents in Tianjin

verfasst von: Yingyi Zhang, Hua Yang, Ruiying Wang, Fumei Zhao, Ting Liu, Ying Zhang, Zhigang Guo, Hongliang Cong

Erschienen in: Advances in Therapy | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

This study aims to examine the medication prescriptions for hypertension in Tianjin.

Methods

Patients with hypertension in Tianjin were enrolled in this study. The patients’ ages ranged from 35 to 75 years. A questionnaire survey and physical examination were completed to collect clinical data. Thereafter, a statistical analysis of the medication prescriptions was conducted with different age groups and different grades of hypertension.

Results

The results show that, in the total population, and for the young, middle-aged, and older groups, the proportions of single-drug use were 62.97%, 59.26%, 62.76%, and 63.49%, respectively, and the highest rate was for calcium channel blocker (CCB) use. The rates of the two drug classes were 24.51%, 29.63%, 25.13%, and 23.15%, respectively. The drug use rate of CCBs combined with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs) was the highest. The rates of the three drug classes were 4.08%, 4.94%, 4.36%, and 3.52%, respectively, and the highest was ACEI/ARB and CCB combined with diuretics. The rates of the four drug classes were low. Regarding the hypertension grade, in grade 1, grade 2, and grade 3, the rates of single-drug use were 63.53%, 62.69%, and 58.38%, respectively. The rates of the two drug classes were 24.62%, 23.97%, and 25.05%, while the rates of the three drug classes were 3.86%, 4.39%, and 5.34%, respectively.

Conclusion

The rate of single-drug use was high, and the rate of combined drug use in the youth group was slightly higher than in the middle-aged and older age groups. The combination of two drugs was common. In grades 2 and 3 hypertension, the rate of combined drug use remained low.
Literatur
1.
Zurück zum Zitat Ab Majid NL, Omar MA, Khoo YY, Naidu BM, Yn JL, Hasani WS, Rifin HM, Abd Hamid HA, Lourdes TG, Yusoff MF. Prevalence, awareness, treatment and control of hypertension in the Malaysian population: findings from the National Health and Morbidity Survey 2006–2015. J Human Hypertens. 2018;32(8–9):617–24.CrossRef Ab Majid NL, Omar MA, Khoo YY, Naidu BM, Yn JL, Hasani WS, Rifin HM, Abd Hamid HA, Lourdes TG, Yusoff MF. Prevalence, awareness, treatment and control of hypertension in the Malaysian population: findings from the National Health and Morbidity Survey 2006–2015. J Human Hypertens. 2018;32(8–9):617–24.CrossRef
2.
Zurück zum Zitat Diaconu CC, Dediu GN, Iancu MA. Drug-induced arterial hypertension—a frequently ignored cause of secondary hypertension: a review. Acta Cardiol. 2018;1:1–7. Diaconu CC, Dediu GN, Iancu MA. Drug-induced arterial hypertension—a frequently ignored cause of secondary hypertension: a review. Acta Cardiol. 2018;1:1–7.
3.
Zurück zum Zitat Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, et al. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34(5):506–25.CrossRef Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, et al. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34(5):506–25.CrossRef
4.
Zurück zum Zitat Skeete J, Connell K, Ordunez P, DiPette DJ. The American College of Cardiology/American Heart Association 2017 hypertension guideline: implications for incorporation in Latin America, the Caribbean, and other resource-limited settings. J Clin Hypertens. 2018;20(9):1342–9.CrossRef Skeete J, Connell K, Ordunez P, DiPette DJ. The American College of Cardiology/American Heart Association 2017 hypertension guideline: implications for incorporation in Latin America, the Caribbean, and other resource-limited settings. J Clin Hypertens. 2018;20(9):1342–9.CrossRef
5.
Zurück zum Zitat Ab Majid NL, Omar MA, Khoo YY, Naidu BM, Yn JL, Hasani WS, Rifin HM, Abd Hamid HA, Lourdes TG, Yusoff MF. Prevalence, Awareness, Treatment and Control of hypertension in the Malaysian population: findings from the National Health and Morbidity Survey 2006–2015. J Human Hypertens. 2018;32(8–9):617–24.CrossRef Ab Majid NL, Omar MA, Khoo YY, Naidu BM, Yn JL, Hasani WS, Rifin HM, Abd Hamid HA, Lourdes TG, Yusoff MF. Prevalence, Awareness, Treatment and Control of hypertension in the Malaysian population: findings from the National Health and Morbidity Survey 2006–2015. J Human Hypertens. 2018;32(8–9):617–24.CrossRef
6.
Zurück zum Zitat Li Y, Wang L, Feng X, Zhang M, Huang Z, Deng Q, Zhou M, Astell-Burt T, Wang L. Geographical variations in hypertension prevalence, awareness, treatment and control in China: findings from a nationwide and provincially representative survey. J Hypertens. 2018;36(1):178–87.CrossRef Li Y, Wang L, Feng X, Zhang M, Huang Z, Deng Q, Zhou M, Astell-Burt T, Wang L. Geographical variations in hypertension prevalence, awareness, treatment and control in China: findings from a nationwide and provincially representative survey. J Hypertens. 2018;36(1):178–87.CrossRef
7.
Zurück zum Zitat Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, Cheng X, Mu L, Zhang H, Liu J, Su M, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549–58.CrossRef Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, Cheng X, Mu L, Zhang H, Liu J, Su M, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549–58.CrossRef
8.
Zurück zum Zitat Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68.CrossRef Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959–68.CrossRef
9.
Zurück zum Zitat Gąsowski J, Piotrowicz K, Messerli FH. Arterial hypertension after age 65: from epidemiology and pathophysiology to therapy Do we know where we stand. Kardiol Pol. 2018;76(4):723–30.CrossRef Gąsowski J, Piotrowicz K, Messerli FH. Arterial hypertension after age 65: from epidemiology and pathophysiology to therapy Do we know where we stand. Kardiol Pol. 2018;76(4):723–30.CrossRef
10.
Zurück zum Zitat Hering D, Kucharska W, Chrostowska M, Narkiewicz K. Age-dependent sympathetic neural responses to ß1 selective beta-blockade in untreated hypertension-related tachycardia. Blood Press. 2018;27(3):158–65.CrossRef Hering D, Kucharska W, Chrostowska M, Narkiewicz K. Age-dependent sympathetic neural responses to ß1 selective beta-blockade in untreated hypertension-related tachycardia. Blood Press. 2018;27(3):158–65.CrossRef
11.
Zurück zum Zitat Ishida T, Akinori Oh, Hiroi S, Shimasaki Y, Tsuchihashi T. Current use of antihypertensive drugs in Japanese patients with hypertension: analysis by age group. Geriatr Gerontol Int. 2018;18(6):899–906.CrossRef Ishida T, Akinori Oh, Hiroi S, Shimasaki Y, Tsuchihashi T. Current use of antihypertensive drugs in Japanese patients with hypertension: analysis by age group. Geriatr Gerontol Int. 2018;18(6):899–906.CrossRef
12.
Zurück zum Zitat Cuspidi C, Tadic M, Grassi G, Mancia G. Treatment of hypertension: The ESH/ESC guidelines recommendations. Pharmacol Res. 2018;128:315–21.CrossRef Cuspidi C, Tadic M, Grassi G, Mancia G. Treatment of hypertension: The ESH/ESC guidelines recommendations. Pharmacol Res. 2018;128:315–21.CrossRef
13.
Zurück zum Zitat Peng S, Shen T, Liu J, Tomlinson B, Sun H, Chen X, Chan P, Kuang YaShu, Zheng L, et al. Uncontrolled hypertension increases with age in an older community-dwelling chinese population in Shanghai. Aging Dis. 2017;8(5):558–69.CrossRef Peng S, Shen T, Liu J, Tomlinson B, Sun H, Chen X, Chan P, Kuang YaShu, Zheng L, et al. Uncontrolled hypertension increases with age in an older community-dwelling chinese population in Shanghai. Aging Dis. 2017;8(5):558–69.CrossRef
14.
Zurück zum Zitat Derington CG, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, national health and nutrition examination survey 2005–2016. Hypertension. 2020;75:973–81.CrossRef Derington CG, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, national health and nutrition examination survey 2005–2016. Hypertension. 2020;75:973–81.CrossRef
15.
Zurück zum Zitat Nowak R, Kucharska W, Boutouyrie P. Sympathetic nerve activity is independently linked to geometric and elastic properties of common carotid artery in resistant hypertension. J Hypertens. 2017;35:e76–e7777. Nowak R, Kucharska W, Boutouyrie P. Sympathetic nerve activity is independently linked to geometric and elastic properties of common carotid artery in resistant hypertension. J Hypertens. 2017;35:e76–e7777.
16.
Zurück zum Zitat Matsukawa T, Mano T, Gotoh E, Ishii M. Elevated sympathetic nerve activity in patients with accelerated essential hypertension. J Clin Investig. 1993;92(1):25–8.CrossRef Matsukawa T, Mano T, Gotoh E, Ishii M. Elevated sympathetic nerve activity in patients with accelerated essential hypertension. J Clin Investig. 1993;92(1):25–8.CrossRef
17.
Zurück zum Zitat Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension. 1989;13(6 Pt 2):870–7.CrossRef Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension. 1989;13(6 Pt 2):870–7.CrossRef
18.
Zurück zum Zitat Collins KJ. Age-related changes in autonomic control: the use of beta blockers in the treatment of hypertension. Cardiovasc Drugs Ther. 1991;4(Suppl 6):1257–62.CrossRef Collins KJ. Age-related changes in autonomic control: the use of beta blockers in the treatment of hypertension. Cardiovasc Drugs Ther. 1991;4(Suppl 6):1257–62.CrossRef
19.
Zurück zum Zitat Kuyper LM, Khan NA. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol. 2014;30(5 Suppl):S47–53.CrossRef Kuyper LM, Khan NA. Atenolol vs nonatenolol β-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol. 2014;30(5 Suppl):S47–53.CrossRef
20.
Zurück zum Zitat Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens. 2011;24(11):1181–6.CrossRef Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens. 2011;24(11):1181–6.CrossRef
21.
Zurück zum Zitat Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH III, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792–801.CrossRef Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH III, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792–801.CrossRef
Metadaten
Titel
An Analysis of Medication Prescriptions for Hypertension in Urban and Rural Residents in Tianjin
verfasst von
Yingyi Zhang
Hua Yang
Ruiying Wang
Fumei Zhao
Ting Liu
Ying Zhang
Zhigang Guo
Hongliang Cong
Publikationsdatum
28.08.2020
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 10/2020
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01475-y

Weitere Artikel der Ausgabe 10/2020

Advances in Therapy 10/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.